Elicio Phase 2 AMPLIFY-7P misses primary DFS endpoint; positive R0 subgroup guides Phase 3

Elicio Therapeutics, Inc.

AMPLIFY-7P did not meet primary endpoint of DFS in ITT; R1 resection imbalance (19% vs 10%) favored observation arm.
Post-hoc analysis in R0 patients showed HR 0.65 (p=0.048); mDFS 23.8 mo vs 12.8 mo; 84% of study population.
mKRAS-specific T cell responses strongly correlated with DFS (HR 0.22, p<0.0001, n=90).
Refined Phase 3 plan targets R0 resected patients with additional dosing; cash runway into Q4 2026; exploring financing.
Favorable safety: no treatment-related discontinuations or deaths.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.